Verastem Q1 adjusted loss narrows smaller than expected on recording revenue

Verastem

07/05/2026 21:14

Overview

U.S. cancer drug maker's Q1 adjusted EPS beat analyst expectations

Q1 net product revenue was $18.7 mln, reflecting first full year of commercial sales

Company appointed Daniel Lyons as chief commercial officer and launched three Phase 2 trials

Outlook

Company expects cash runway into first half of 2027

Verastem to report early data from TARGET-D 101 trial in 1H 2026 and mature data in 2H 2026

Company plans topline readout of RAMP 301 trial in mid-2027

Result Drivers

FIRST FULL YEAR SALES - Q1 net product revenue of $18.7 mln driven by first full year of AVMAPKI FAKZYNJA CO-PACK commercial sales

HIGHER R&D AND SG&A COSTS - Operating expenses rose due to increased research and development spending and higher personnel and commercial operations costs

Company press release: ID:nBw6VGwD7a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Adjusted EPS
Beat
-$0.43
-$0.46 (9 Analysts)
Q1 EPS
-$0.46
Q1 Net Income
-$36.59 mln
Q1 Income from Operations
-$44.90 mln
Q1 Operating Expenses
$63.57 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Verastem Inc is $16.00, about 166.2% above its May 6 closing price of $6.01

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)